Want to see HK:2162 full AI Analyst Report?
2162 Stock Chart & Stats
HK$62.80
HK$0.80(2.86%)
At close: 4:00 PM EST
HK$62.80
HK$0.80(2.86%)
Day’s Range― - ―
52-Week RangeHK$44.45 - HK$81.85
Previous CloseN/A
Volume918.50K
Average Volume (3M)1.75M
Market Cap
HK$22.84B
Enterprise ValueHK$14.44B
Total Cash (Recent Filing)HK$1.96B
Total Debt (Recent Filing)HK$788.88M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Sep 01, 2026EPS Estimate
6.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding298,735,570
10 Day Avg. Volume1,976,819
30 Day Avg. Volume1,752,076
Financial Highlights & Ratios
PEG Ratio4.63
Price to Book (P/B)4.74
Price to Sales (P/S)18.85
P/FCF Ratio-12.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$93.24Price Target Upside48.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.77
Revenue Forecast (FY)HK$2.19B
Bulls Say, Bears Say
Bulls Say
Balance-sheet Strength And Moderate LeverageA sizable equity base and modest debt-to-equity provide durable financial capacity to fund R&D and clinical programs without immediate solvency risk. This balance-sheet buffer increases optionality for licensing, partnerships or measured financing, extending runway versus peers.
High Gross Margin ProfileSustained ~74% gross margins signal strong product or platform economics if candidates commercialize. High gross margins support scalable profitability once fixed R&D and SG&A are controlled, improving long-term operating leverage and cash conversion potential.
Licensing And Partnership-driven Revenue ModelA business model emphasizing out-licensing and collaborations enables non-dilutive milestone and royalty income, risk-sharing on late-stage costs, and access to partner commercialization expertise — structural strengths for capital efficiency and market reach over time.
Bears Say
Sustained Negative Operating And Free Cash FlowPersistent large cash burn limits internal funding for trials and commercialization, forcing reliance on external financing or partner deals. Over months this elevates dilution or debt risk, constrains strategic flexibility, and can delay value-creating milestones if capital access tightens.
Very Large Operating And Net LossesDeep negative EBIT and net margins indicate the company is far from breakeven and absorbing heavy R&D and operating costs. Persisting losses depress returns on equity, limit retained capital for growth, and increase dependence on external funding over the medium term.
Recent Revenue Decline And Outcome VolatilityAfter multi-year scaling, a ~20% revenue drop in 2025 signals demand or execution variability. Revenue volatility complicates forecasting for funding needs and milestone timing, slowing progress to sustainable margins and increasing execution risk until growth stabilizes.
Keymed Biosciences, Inc. News
2162 FAQ
What was Keymed Biosciences, Inc.’s price range in the past 12 months?
Keymed Biosciences, Inc. lowest stock price was HK$44.45 and its highest was HK$81.85 in the past 12 months.
What is Keymed Biosciences, Inc.’s market cap?
Keymed Biosciences, Inc.’s market cap is HK$22.84B.
When is Keymed Biosciences, Inc.’s upcoming earnings report date?
Keymed Biosciences, Inc.’s upcoming earnings report date is Sep 01, 2026 which is in 57 days.
How were Keymed Biosciences, Inc.’s earnings last quarter?
Keymed Biosciences, Inc. released its earnings results on Mar 26, 2026. The company reported -HK$1.839 earnings per share for the quarter, missing the consensus estimate of -HK$1.501 by -HK$0.338.
Is Keymed Biosciences, Inc. overvalued?
According to Wall Street analysts Keymed Biosciences, Inc.’s price is currently Undervalued.
Does Keymed Biosciences, Inc. pay dividends?
Keymed Biosciences, Inc. does not currently pay dividends.
What is Keymed Biosciences, Inc.’s EPS estimate?
Keymed Biosciences, Inc.’s EPS estimate is 6.58.
How many shares outstanding does Keymed Biosciences, Inc. have?
Keymed Biosciences, Inc. has 298,735,570 shares outstanding.
What happened to Keymed Biosciences, Inc.’s price movement after its last earnings report?
Keymed Biosciences, Inc. reported an EPS of -HK$1.839 in its last earnings report, missing expectations of -HK$1.501. Following the earnings report the stock price went up 0.174%.
Which hedge fund is a major shareholder of Keymed Biosciences, Inc.?
Currently, no hedge funds are holding shares in HK:2162
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keymed Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.01%
12-Months-Change
Fundamentals
Return on Equity
-17.26%
Trailing 12-Months
Asset Growth
17.19%
Trailing 12-Months
Company Description
Keymed Biosciences, Inc.
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
2162 Stock 12 Month Forecast
Average Price Target
HK$93.24
▲(48.46% Upside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---